Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia

Nuclear Medicine and Biology

Volumn 37, Issue 5, 2010, Pages 557-564

  Akurathi, Vamsidhar ^a   Dubois, Ludwig ^b   Lieuwes, Natasja G ^b   Chitneni, Satish K ^c   Cleynhens, Bernard J ^a   Vullo, Daniela ^d   Supuran, Claudiu T ^d   Verbruggen, Alfons M ^a   Lambin, Philippe ^b   Bormans, Guy M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase IX; Sulfonamides; Technetium 99m tricarbonyls; Tumor hypoxia

Indexed keywords

CARBONATE DEHYDRATASE IX; SULFONAMIDE; TECHNETIUM 99M; TRACER; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TECHNETIUM COMPLEX; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL HYPOXIA; DRUG INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; METABOLISM; MOLECULAR IMAGING; PATHOLOGY; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL HYPOXIA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR IMAGING; ORGANOTECHNETIUM COMPOUNDS; SULFONAMIDES;

EID: 77953807572     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.02.006     Document Type: Article

References (34)

1. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008, 11:851-864.
2. Cairns R.A., Khokha R., Hill R.P. Molecular mechanisms of tumor invasion and metastasis: An integrated view. Curr Mol Med 2003, 3:659-671.
3. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia and cancer. J Mol Med 2007, 85:1301-1307.
4. Pennacchietti S., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
5. Harris A.L. Hypoxia a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
6. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996, 56:941-943.
7. Reynolds T.Y., Rockwell S., Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res 1996, 56:5754-5757.
8. Pastorekova S., Pastorek J. C R C enzymes inhibitors series. Carbonic anhydrase-its inhibitors and activators 2005, 255-281. C R.C. Press, London. C.T. Supuran, A. Scozzafava, J. Conway (Eds.).
9. Pastorekova S., Parkkila S., Pastorek J., Supuran C.T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004, 19:199-229.
10. Stubbs M., McSheehy P.M.J., Griffiths J.R., Bashford C.L. Causes and consequences of tumor acidity and implications for treatment. Mol Med Today 2000, 6:15-19.
11. Helmlinger G., Sckell A., Dellian M., Forbes N.S., Jain R.K. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2000, 8:1284-1291.
12. Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., Jain R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001, 61:6020-6024.
13. Martinez-Zaguilan R., Lynch R.M., Martinez G.M., Gillies R.J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1992, 14:176-186.
14. Fischer B., Muller B., Fischer K.G., Baur N., Kreutz W. Acidic pH inhibits non-MHC-restricted killer cell functions. Clin.Immunol. 2000, 96:252-263.
15. Dubois L., Douma K., Supuran C.T., Chiu R.K., van Zandvoort M.A., Pastorekova S., et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 2007, 83:367-373.
16. 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003, 105:873-881.
17. Stillebroer A.B., Oosterwijk E., Oyen W.J.G., Mulders P.F.A., Boerman O.C. Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging 2007, 7:179-188.
18. Supuran C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discovery 2008, 7:168-181.
19. Svastova E., Hulikova A., Rafajova M., Zatovicova M., Gibadulinova A., Casini A., et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004, 577:439-445.
20. Casey J.R., Morgan P.E., Vullo D., Scozzafava A., Mastrolorenzo A., Supuran C.T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004, 47:2337-2347.
21. Jonathan R.D., Suzanne J.P. The biomedical chemistry of technetium and rhenium. Chem Soc Rev 1998, 27:43-55.
22. Kieffer D., Cleynhens B., Vanbilloen H., Rattat D., Terwinghe C., Mortelmans L., et al. Synthesis and biological evaluation of a technetium-99m(I)-tricarbonyl-labelled phenyltropane derivative. Bioorg Med Chem Lett 2006, 16:382-386.
23. 3 complexes with a tridentate ligand. Bioorg Med Chem Lett 2005, 15:4192-4195.
24. Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003, 13:1005-1009.
25. Vullo D., Innocenti A., Nishimori I., Pastorek J., Scozzafava A., Pastorekova S., et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs. Bioorg Med Chem Lett 2005, 15:963-969.
26. 3(NNO) complexes (M=Re, 99mTc) conjugated to 2-(4-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals. J Med Chem 2006, 49:5408-5410.
27. 99mTc-BAT-tropane esters. Nucl Med Biol 2005, 32:607-612.
28. Khalifah R.G.T. The carbon dioxide hydration activity of carbonic anhydrase. J. Biol. Chem 1971, 246(8):2561-2573.
29. Singh J., Wyeth P. The enzyme inhibitor approach to cell selective labeling sulfonamide inhibitor. Sulfonamid inhibitors of carbonic anhydrase as carriers for red cell labeling in vitro uptake of PIBS by human red blood cells. Appl. Radiat. Isot 1991, 42:251-259.
30. Yamazaki M., Akiyama S., Nishigaki R., Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady state in rats. Pharm Res 1996, 10:1559-1564.
31. Shin K.H., Diaz-Gonzalez J.A., Russell J., Chen Q., Burgman P., Li X.F., et al. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 2007, 6:70-75.
32. Purkerson J.M., Schwartz G.J. The role of carbonic anhydrases in renal physiology. Kidney Int 2007, 71:103-115.
33. Pastorekova S., Parkkila S., Zavada J. Tumor associated carbonic anhydrases and their clinical significance. Advances in clinical chemistry 2006, 42:167-216.
34. Bussink J., Kaanders J.H.A.M., van der Kogel A.J. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003, 67:3-15.